



CURE & Yale OCR present the
Yale
BIOHAVEN
entrepreneurship series
2007 - 2008

Tuesday, November 13, 2007
Vascular Insights LLC



Followed by networking, refreshments & wine bar

Market estimates suggest that varicose vein disease affects between 75 and 150 million people in North America and Western Europe, making the market for varicose vein disease one of the largest markets for any chronic condition in the developed world.

While the number of people suffering from varicose vein disease is high, only about 1-2% of sufferers actually obtain treatment. This omission is in large part due to the unsatisfactory characteristics and trauma of existing treatments, including surgery and laser and radiofrequency ablation.

With technology licensed from Yale University and its own intellectual property, Vascular Insights is developing the ClariVein-VA™ vascular ablation device. The device allows varicose vein disease correction with a simple-to-use, minimally invasive, small caliber (2 2/3 French), soft, flexible infusion catheter.

While reducing procedure time, ClariVein-VA™ requires no anesthetic, no surgery, no hospitalization and no discomfort. A vascular sheath is unnecessary and wire exchanges are eliminated, no tumescent anesthetic is required, and there is no costly, cumbersome generator to buy, lease, or maintain.

With seed funding in place, the company is currently seeking strategic partners to share risk and accelerate product development.

Note: The FDA has not as yet cleared ClariVein-VA™ for marketing in the US.

Speakers

John P. Marano, Jr., Ph.D.
Michael Tal, M.D.

Co-Founder, President & CEO, Vascular Insights LLC
Associate Professor of Radiology, Yale School of Medicine; Co-Founder
and Chief Medical Advisor, Vascular Insights LLC

Tuesday, November 13, 2007

3:30 P.M. Registration

4:00 P.M. Seminar

5:00 P.M. Networking, Refreshments & Wine Bar

Location

The Anlyan Center auditorium, Yale Medical School.

Directions & Parking:

<http://info.med.yale.edu/maps/cab.html>

RSVP

Registration is free, but please RSVP in advance. E-mail to biohaven@yale.edu or call the Yale OCR main number: 203-785-6209.

Mark Your Calendar

The next seminar in the series, on **February 20, 2008**, features Rib-X Pharmaceuticals. [Download a brochure of the complete 2007-2008 series here.](#)

Lead sponsors: Wiggin and Dana and PricewaterhouseCoopers.



Also sponsored by Elm Street Ventures.



Presented by CURE and the Yale Office of Cooperative Research.



Additional support from the Yale Entrepreneurial Society and the Yale Biotechnology & Pharmaceutical Society.



Published by Connecticut United for Research Excellence
Copyright © 2007 Connecticut United for Research Excellence. All rights reserved.
Visit CURE at <http://curenet.org> and BioBus Educational Programs at <http://ctbiobus.org>

TELL A FRIEND

Powered by **IMN™**